| NCT06552416 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS | RECRUITING | PHASE1 | 2025-06-16 | 2029-09 | 2029-09 |
| NCT06549751 | MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer | NOT_YET_RECRUITING | PHASE1 | 2024-09 | 2027-12 | 2027-09 |
| NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | RECRUITING | PHASE1 | 2023-01-02 | 2028-02-28 | 2028-02-28 |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant | COMPLETED | PHASE2 | 2020-10-14 | 2024-03-01 | 2024-03-01 |
| NCT04358003 | Plasma Adsorption in Patients With Confirmed COVID-19 | COMPLETED | NA | 2020-05-20 | 2022-04-01 | 2021-11-26 |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | TERMINATED | PHASE2 | 2017-07-20 | 2020-01-15 | 2020-01-15 |
| NCT02593227 | Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | COMPLETED | PHASE2 | 2016-04 | 2021-07-15 | 2021-07-15 |